[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.87.121.0. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
November 2, 1994

Treatment of Metastatic Melanoma and Renal Cell Carcinoma With Interleukin-2

Author Affiliations

University of Pennsylvania Philadelphia

JAMA. 1994;272(17):1327. doi:10.1001/jama.1994.03520170037027
Abstract

To the Editor.  —Dr Rosenberg and colleagues1 report 5 years of experience in treating patients with metastatic melanoma or renal cell cancer with interleukin-2. The poor clinical results that they achieved over that time (7% success rate compared with the spontaneous success rate of 5%) may be caused by an error in the model design on which their protocols were based. In their model experiments with immunogenic mouse tumors,2 treatment of the tumor-bearing mice with interleukin-2 and tumor-infiltrating lymphocyte cells began 3 days after transplanting the tumor into the syngeneic host. They used the phrase "established pulmonary micrometastases" to describe the characteristics of the system, implying that 3 days after transplantation, the tumors had acquired the in vivo characteristics of an autochthonous tumor.These authors have overlooked reports from my laboratory that were published in 1977 that showed that immunogenic mouse tumor cells became "killer cell" resistant by

First Page Preview View Large
First page PDF preview
First page PDF preview
×